The Israeli generic drug maker, known for its aggressive tactics, is getting a taste of its own medicine if Pittsburgh based, Mylan has anything to say about it. (I can’t get enough of the: “taste of its own medicine" line.)
TEVA markets a proprietary, branded drug for MS called glatiramer acetate (COPAXONE), sold $1.7B worth of the drug last year and is on pace to top $2B this year. The patent doesn’t expire until 2014 but Mylan (after signing an agreement with the India based NATCO) is threating sales in the US, EU, Canada and Japan, among others.
There is still a long road to market due to the whole pesky patent issue, but I’m sure we’ll soon see a challenge and some interesting fireworks.
In conclusion: TEVA gets a taste of its own medicine.